Up a level |
Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany (In Press). PharmacoEconomics Open Springer 10.1007/s41669-024-00480-z
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441